Amping up With PemJAK

Part of paid clinical trials in New York, New York.

Sponsor
Seda S. Tolu
Study ID
NCT07283822
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 95 Years
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    Patients will receive the study drug ruxolitinib for as long as the disease responds, for up to a maximum of one year (or 17 cycles). After study treatment with ruxolitinib is finished, the study doctor will continue to watch for side effects and follow the condition for one year. If any side effects are experienced, the study doctor will follow up until resolution or stabilization of the side effect.
  • Pembrolizumab — DRUG
    Pembrolizumab immunotherapy will be administered intravenously at 200 mg once every 21 days. Subjects will receive pembrolizumab for as long as the disease responds, up to a maximum of one year (or 17 cycles). Each cycle is 21 days long.

Study Details

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

Key Dates

Start date
Dec 3, 2025
Status verified
Dec 2025
Primary completion
Jan 31, 2028
Completion
Jan 31, 2029

Study Design

Enrollment
53 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib
    Ruxolitinib 20mg PO twice daily will be continued until 12 months, disease progression, or development of intolerable side effects (whichever occurs first).

Primary Outcome Measure

Complete Response (CR) rate [ Time Frame: 24 months from the start of study treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Columbia University Irving Medical CenterNew YorkNew York10032
Research Nurse Navigator, RN
[email protected]
212-342-5162
Seda Tolu, MD
[email protected]
212-305-8923

Find similar trials in New York, NY

By research site
Columbia University Irving Medical Center· New York, NY

Related Studies